Mieko Toyoda

Cedars-Sinai Medical Center — United States

Medicine · Health Sciences

42h-index6.8kcitations149works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal Transplantation Outcomes and Treatments(38), Cytomegalovirus and herpesvirus research(33), Immune Cell Function and Interaction(31), T-cell and B-cell Immunology(19), Immunodeficiency and Autoimmune Disorders(19)

Publications149 total

T-cell Immunity Against COVID-19 and UK Variant in Infected and Vaccinated Individuals
2024Open Access
Viral‐specific cytotoxic T‐cell responses in HLA‐sensitized kidney transplant patients maintained on everolimus and low‐dose tacrolimus
Transplant Infectious Disease·2022· 1 cited
Evaluation of Clazakizumab (Anti–Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts
Kidney International Reports·2022· 52 citedOpen Access
Clazakizumab for desensitization in highly sensitized patients awaiting transplantation
American Journal of Transplantation·2021· 41 cited
Divergent Immune Responses to SARS-CoV-2 Vaccines in Immunocompromised Patients
Transplantation·2021· 6 citedOpen Access
T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals
Cellular and Molecular Immunology·2021· 90 citedOpen Access
Use of Rituximab for persistent EBV DNAemia, and Its effect on donor‐specific antibody development in pediatric renal transplant recipients: A case series
Pediatric Transplantation·2021· 10 cited
Development of CMV‐specific cytotoxic T cells (CMV‐Tc) in pediatric renal transplant recipients with CMV viremia
Pediatric Transplantation·2021· 1 cited
CLAZAKIZUMAB® (ANTI-IL-6) FOR DESENSITIZATION OF HIGHLY-HLA SENSITIZED PATIENTS AWAITING KIDNEY TRANSPLANT (NCT03380962)
Transplantation·2020· 7 cited
CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WITH CHRONIC & ACTIVE ANTIBODY-MEDIATED REJECTION POST-KIDNEY TRANSPLANTATION (NCT03380377)
Transplantation·2020· 4 cited
CLAZAKIZUMAB (ANTI-IL-6) INDUCES FOXP3+ TREGS IN HIGHLY HLA SENSITIZED PATIENTS RECEIVING HLAI KIDNEY TRANSPLANTATION (NCT03380962)
Transplantation·2020· 5 cited
Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia
Clinical Infectious Diseases·2020· 88 citedOpen Access
The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection
American Journal of Transplantation·2020· 43 citedOpen Access
Interleukin-6: An Important Mediator of Allograft Injury
Transplantation·2020· 64 cited
Imlifidase Inhibits HLA Antibody-mediated NK Cell Activation and Antibody-dependent Cell-mediated Cytotoxicity (ADCC) In Vitro
Transplantation·2019· 37 citedOpen Access
Impact of Tocilizumab (Anti–IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection
Transplantation·2019· 66 cited
Interleukin 6: Pathogenic Potential and Therapeutic Approaches in Autoimmunity and Transplant Rejection
Encyclopedia of Life Sciences·2018· 3 cited
Novel Therapeutic Approaches to Allosensitization and Antibody-mediated Rejection
Transplantation·2018· 32 cited
IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation
New England Journal of Medicine·2017· 351 citedOpen Access
Plasma Exosomes From HLA-Sensitized Kidney Transplant Recipients Contain mRNA Transcripts Which Predict Development of Antibody-Mediated Rejection
Transplantation·2017· 58 cited
page 1 of 8Next →

Frequent Co-authors

Stanley C. Jordan(48), Ashley Vo(36), Alice Peng(19), Jua Choi(14), Shili Ge(11), Joseph Kahwaji(11), Rafael Villicana(8), Nancy L. Reinsmoen(7), Mark Haas(7), Suphamai Bunnapradist(7), Dechu Puliyanda(7), Edmund Huang(7), Dolly B. Tyan(6), Noriko Ammerman(6), Cynthia C. Nast(5), Asha Moudgil(5), Odette A. Galera(5), Anna Petrosian(5), Marina Lukovsky(4), Chih‐Hung Lai(4)